4.8 Article

PDK1 Is a Regulator of Epidermal Differentiation that Activates and Organizes Asymmetric Cell Division

Journal

CELL REPORTS
Volume 15, Issue 8, Pages 1615-1623

Publisher

CELL PRESS
DOI: 10.1016/j.celrep.2016.04.051

Keywords

-

Categories

Funding

  1. SDRC Pilot & Feasibility Studies Program [P30AR44535]
  2. Uehara Memorial Foundation Research Fellowship
  3. Japanese Society for Investigative Dermatology (JSID)'s Fellowship SHISEIDO Award
  4. Japan Society for the Promotion of Science (JSPS) KAKENHI [26670529]
  5. NIH [R37-AI33443]
  6. Grants-in-Aid for Scientific Research [15H05790, 26670529] Funding Source: KAKEN

Ask authors/readers for more resources

Asymmetric cell division (ACD) in a perpendicular orientation promotes cell differentiation and organizes the stratified epithelium. However, the upstream cues regulating ACD have not been identified. Here, we report that phosphoinositide-dependent kinase 1 (PDK1) plays a critical role in establishing ACD in the epithelium. Production of phosphatidyl inositol triphosphate (PIP3) is localized to the apical side of basal cells. Asymmetric recruitment of atypical protein kinase C (aPKC) and partitioning defective (PAR) 3 is impaired in PDK1 conditional knockout (CKO) epidermis. PDK1(CKO) keratinocytes do not undergo calcium-induced activation of aPKC or IGF1-induced activation of AKT and fail to differentiate. PDK1(CKO) epidermis shows decreased expression of Notch, a downstream effector of ACD, and restoration of Notch rescues defective expression of differentiation-induced Notch targets in vitro. We therefore propose that PDK1 signaling regulates the basal-to-suprabasal switch in developing epidermis by acting as both an activator and organizer of ACD and the Notch-dependent differentiation program.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Infectious Diseases

The second nationwide surveillance of antibacterial susceptibility patterns of pathogens isolated from skin and soft-tissue infections in dermatology departments in Japan

Takamitsu Ohnishi, Shinichi Watanabe, Tetsuya Matsumoto, Hiroshi Yotsuyanagi, Junko Sato, Intestu Kobayashi, Shin Iinuma, Takashi Nagayama, Shuichiro Shibuya, Natsuki Ogawa, Ken Iozumi, Yasuyuki Nakajima, Yukiko Kurikawa, Motoko Kobayashi, Koma Matsuo, Hideyuki Ishikawa, Tadamichi Shimizu, Kiyohiro Tsutsui, Tatsuyoshi Kawamura, Ryuhei Okuyama, Mariko Seishima, Yoichi Akita, Chikatoshi Kasugai, Katsuaki Yano, Yasuhiko Tamada, Kimihiko Mizutani, Kenji Kabashima, Nanako Yamada, Masami Ikeda

Summary: The present study compared trends in antimicrobial resistance patterns in pathogens isolated from skin and soft-tissue infections (SSTIs) in Japan with those of a nationwide survey conducted in 2013. The prevalence of methicillin-resistant Staphylococcus aureus (MRSA) did not differ significantly between the present study and the 2013 survey. However, the prevalence of methicillin-resistant coagulase-negative staphylococci (MRCNS) was higher in the present study compared to the 2013 survey. The susceptibility profiles of MRSA and MRCNS to various antibiotics were not significantly different between the two surveys. Continuous monitoring is important for guiding the appropriate treatment of SSTIs.

JOURNAL OF INFECTION AND CHEMOTHERAPY (2023)

Letter Dermatology

Non-invasive visualization of epidermal hypertrophy of pachydermoperiostosis

Takayoshi Komatsu-Fujii, Corrine Sison de Jesus, Takashi Nomura, Kenji Kabashima

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Dermatology

The effects of systemic immunomodulatory treatments on COVID-19 outcomes in patients with atopic dermatitis: Results from the global SECURE-AD registry

Annelie H. Musters, Conor Broderick, David Prieto-Merino, Andrea Chiricozzi, Giovanni Damiani, Ketty Peris, Sandipan Dhar, Abhishek De, Esther Freeman, Bernd W. M. Arents, Tim Burton, Angela Leigh-Ann L. Bosma, Ching-Chi Chi, Godfrey Fletcher, Aaron M. Drucker, Kenji Kabashima, Emilie F. de Monchy, Maitreyee Panda, Dmitri Robert Wall, Christian Vestergaard, Emmanuel Mahe, Laura Bonzano, Leila Kattach, Maddalena Napolitano, Maria Fernanda Ordonez-Rubiano, Eva Haufe, Cataldo Patruno, Alan D. Irvine, Phyllis Spuls, Carsten Flohr

Summary: Limited data suggest that patients with atopic dermatitis (AD) receiving systemic immunomodulatory treatments have a lower risk of severe COVID-19 complications. Monotherapy with dupilumab is associated with lower hospitalization rates compared to other therapies. However, combination systemic treatments, particularly those including systemic corticosteroids, have the highest risk of severe COVID-19.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Dermatology

English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors in the treatments of atopic dermatitis

Hidehisa Saeki, Masashi Akiyama, Masatoshi Abe, Atsuyuki Igarashi, Shinichi Imafuku, Yukihiro Ohya, Norito Katoh, Hideto Kameda, Kenji Kabashima, Yuichiro Tsunemi, Michihiro Hide, Mamitaro Ohtsuki

Summary: This guidance provides information on the use of oral JAK inhibitors for the treatment of atopic dermatitis. It explains the role of oral JAK inhibitors in inhibiting the signal transduction of cytokines involved in the pathogenesis of atopic dermatitis. It also highlights the authorized oral JAK inhibitors for atopic dermatitis in Japan and emphasizes the importance of considering disease factors, treatment factors, and patient backgrounds in the selection of treatment options.

JOURNAL OF DERMATOLOGY (2023)

Review Dermatology

Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent events

R. Bissonnette, L. F. Eichenfield, E. Simpson, D. Thaci, K. Kabashima, J. P. Thyssen, E. Guttman-Yassky, F. P. Nunes, M. Gamalo, F. Ahmad, M. Kuligowski, K. Sun, C. Pipper, A. W. Christensen, P. D'Angelo, M. Milutinovic, A. Guettner, J. I. Silverberg

Summary: Despite the lack of guidelines for analyzing clinical trial data in atopic dermatitis (AD), using the estimand framework can help standardize the analysis and incorporate intercurrent events. Intercurrent events, such as rescue therapy and sleep deprivation, frequently occur in AD trials and their inconsistent handling limits result interpretation. Applying the estimand framework, as guided by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), can improve AD trial design and analysis by providing more reflective and informative results for clinicians to make treatment selection.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Medicine, General & Internal

An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study

Emma Guttman-Yassky, Eric L. Simpson, Kristian Reich, Kenji Kabashima, Ken Igawa, Tetsuya Suzuki, Hirotaka Mano, Takeshi Matsui, Ehsanollah Esfandiari, Masutaka Furue

Summary: This study evaluated the efficacy and safety of the anti-OX40 antibody rocatinlimab in patients with moderate-to-severe atopic dermatitis. The results showed significant reductions in EASI score at week 16 in patients receiving rocatinlimab compared to placebo. The treatment led to progressive improvements in atopic dermatitis, which were maintained in most patients after treatment discontinuation, and it was well tolerated.

LANCET (2023)

Article Dermatology

Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis A Post Hoc Analysis of 6 Randomized Clinical Trials

Amy S. Paller, Jonathan I. Silverberg, Michael J. Cork, Emma Guttman-Yassky, Benjamin Lockshin, Alan D. Irvine, Moon Bum Kim, Kenji Kabashima, Zhen Chen, Yufang Lu, Ashish Bansal, Ana B. Rossi, Arsalan Shabbir

Summary: This study assessed the efficacy and safety of dupilumab in patients with severe erythrodermic atopic dermatitis (AD). The results showed that dupilumab significantly improved AD signs and symptoms, including affected body surface area, Eczema Area and Severity Index (EASI) score, and Pruritus Numerical Rating Scale (PP-NRS) score. The treatment also led to reductions in serum biomarker levels.

JAMA DERMATOLOGY (2023)

Article Allergy

Summary of the current status of clinically diagnosed cases of Schnitzler syndrome in Japan

Riko Takimoto-Ito, Naotomo Kambe, Toshiaki Kogame, Takashi Nomura, Kazushi Izawa, Tomoyasu Jo, Yasuhiro Kazuma, Hajime Yoshifuji, Yuya Tabuchi, Hiroyasu Abe, Mayuko Yamamoto, Kimiko Nakajima, Ozumi Tomita, Yosuke Yagi, Kazumoto Katagiri, Yuki Matsuzaka, Yohei Takeuchi, Miho Hatanaka, Takuro Kanekura, Sora Takeuchi, Takafumi Kadono, Yuya Fujita, Kiyoshi Migita, Takahiro Fujino, Takahiko Akagi, Tomoyuki Mukai, Tohru Nagano, Mitsuhiro Kawano, Hayato Kimura, Yukari Okubo, Akimichi Morita, Michihiro Hide, Takahiro Satoh, Akihiko Asahina, Nobuo Kanazawa, Kenji Kabashima

Summary: Schnitzler syndrome is a rare disorder characterized by chronic urticaria. A nationwide survey was conducted in Japan to determine the current status of the disease. Clinical information of 36 diagnosed cases was collected, providing insights into the clinical features and treatment of the syndrome. Continuous collection and long-term follow-up of clinical information are crucial for the appropriate management and further understanding of Schnitzler syndrome.

ALLERGOLOGY INTERNATIONAL (2023)

Review Immunology

Mast cells in type 2 skin inflammation: Maintenance and function

Yuki Honda Keith, Gyohei Egawa, Tetsuya Honda, Kenji Kabashima

Summary: Mast cells (MCs) are immune cells that play important roles in maintaining homeostasis and inflammatory states in tissues. They are involved in the pathogenesis of type 2 skin inflammation in atopic dermatitis (AD) through both pro- and anti-inflammatory effects. The activation of skin MCs by environmental factors like Staphylococcus aureus can lead to AD inflammation, while MCs also contribute to pruritus through IgE-dependent and -independent degranulation. On the other hand, MCs can suppress type 2 skin inflammation by promoting Treg expansion and enhancing skin barrier function.

EUROPEAN JOURNAL OF IMMUNOLOGY (2023)

Article Biochemistry & Molecular Biology

PlmCas12e (CasX2) cleavage of CCR5: impact of guide RNA spacer length and PAM sequence on cleavage activity

David A. Armstrong, Taylor R. Hudson, Christine A. Hodge, Thomas H. Hampton, Alexandra L. Howell, Matthew S. Hayden

Summary: Gene editing using CRISPR/Cas is a developing therapeutic tool for gene modification in eukaryotic cells. Alternative CRISPR systems, including CasX1 and CasX2, have been identified from non-pathogenic microbes, offering smaller size and selective protospacer adjacent motif (PAM). Research on CasX2 cleavage activity in modifying the CCR5 gene showed variations dependent on target site, spacer length, and the fourth nucleotide in the PAM sequence, indicating the importance for developing gene therapy strategies.

RNA BIOLOGY (2023)

Article Dermatology

Nemolizumab Improves Patient-Reported Symptoms of Atopic Dermatitis with Pruritus: Post Hoc Analysis of a Japanese Phase III Randomized Controlled Trial

Kenji Kabashima, Takayo Matsumura, Hiroshi Komazaki, Makoto Kawashima

Summary: This study investigated the impact of nemolizumab on the quality of life in patients with atopic dermatitis. The results showed that nemolizumab treatment improved sleep quality, interpersonal relationships, and work activities.

DERMATOLOGY AND THERAPY (2023)

Article Biochemistry & Molecular Biology

Mead acid inhibits retinol-induced irritant contact dermatitis via peroxisome proliferator-activated receptor alpha

Azusa Saika, Prabha Tiwari, Takahiro Nagatake, Eri Node, Koji Hosomi, Tetsuya Honda, Kenji Kabashima, Jun Kunisawa

Summary: Mead acid can suppress retinol-induced irritant contact dermatitis and prevent keratinocyte hyperproliferation and the expression of neutrophil chemoattractants through the PPAR-alpha pathway.

FRONTIERS IN MOLECULAR BIOSCIENCES (2023)

Review Immunology

Exploring the role of Janus kinase (JAK) in atopic dermatitis: a review of molecular mechanisms and therapeutic strategies

Toshiaki Kogame, Gyohei Egawa, Kenji Kabashima

Summary: Recent studies have shown that Janus kinase (JAK) plays a crucial role in signal transduction for inflammatory diseases like atopic dermatitis (AD). Clinical trials using JAK inhibitors and biologic reagents have been successful in treating AD, indicating the efficacy of molecular-based therapies. However, there are concerns about the safety of JAK inhibitors, including severe heart disease. This article provides an overview of the molecular mechanisms of AD and discusses JAK-related biology as a target for AD treatment.

IMMUNOLOGICAL MEDICINE (2023)

Article Oncology

MDR1-EXPRESSING CD4+ T CELLS WITH TH1.17 FEATURES RESIST TO NEOADJUVANT CHEMOTHERAPY AND ARE ASSOCIATED WITH BREAST CANCER CLINICAL RESPONSE

Anthony Di Roio, Margaux Hubert, Laurie Besson, Marion Bossennec, Celine Rodriguez, Yenkel Grinberg-Bleyer, Guilhem Lalle, Lyvia Moudombi, Raphael Schneider, Cyril Degletagne, Isabelle Treilleux, Daniel J. Campbell, Severine Metzger, Thomas Duhen, Olivier Tredan, Christophe Caux, Christine Menetrier-Caux

Summary: This study investigated the expression, function, and regulation of MDR1 in CD4(+) T cells and its role in neoadjuvant chemotherapy in breast cancer. The results showed that MDR1 expression was associated with the enrichment of Th1.17 and Th17 cells and correlated positively with pathological response. This study has important clinical implications for adjusting chemotherapy regimens.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Article Dermatology

Neutrophilic epitheliotropism, proposed as an auto-inflammatory condition of neutrophilic urticarial dermatosis including Schnitzler syndrome, is also observed in Japanese cases

Hitomi Nakaizumi, Naotomo Kambe, Hiroyuki Irie, Yo Kaku, Masakazu Fujimoto, Hajime Yoshifuji, Yasuhiro Kazuma, Kazumoto Katagiri, Takuro Kanekura, Kenji Kabashima

Summary: Schnitzler syndrome (SchS) is a rare autoinflammatory disease characterized by bone pain, recurrent fever, and other symptoms. A key feature of the syndrome is the presence of a persistent urticarial-like rash. Histopathological data suggests that neutrophilic epitheliotropism, or the tendency of neutrophils to infiltrate and affect epithelial tissue, can be a useful marker for diagnosing SchS and differentiating it from conventional urticaria. Understanding this characteristic is crucial for early diagnosis and appropriate treatment.

JOURNAL OF DERMATOLOGY (2023)

No Data Available